 |
|
| | |
|
|
| .
1462
The Hirsch Pharmacy is opened in Frankfurt am Main. The Fresenius family assumes ownership in the 18th century.
1912
The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius.
Its main products are pharmaceutical specialities such as injection solutions, serologic reagents and Bormelin nasal ointment.
1933/34
The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees.
1966
Fresenius starts to sell dialysis machines and dialyser manufactured various foreign companies and gains substantial market shares.
1971/72
Introduction of a novel amino acid solution achieving a decisive breakthrough in parenteral nutrition therapy. Development of an innovative volume replacement solution (hydroxyethyl starch solution - HES) in the field of fluid therapy/blood substitution.
1974
Fresenius starts to manufacture infusion solutions and medical disposables in St. Wendel, Saarland.
1979
The first ready-to use tube feed Fresubin® was introduced.
1980
Introduction of HAES-steril®, a further development of the hydroxyethyl starch solution with which Fresenius sets worldwide standards in volume therapy.
1981
Establishment of the home care concept by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. At the same time expansion of the enteral nutrition range.
1988
The within Fresenius developed Aminomix® Two-Chamber-Bag for parenteral nutrition launched.
1993
Launch of Supportan®, a tube feed for enteral nutrition in oncology.
1995
Laying of the cornerstone of the innovative infusion solution plant in Friedberg (Hesse).
1997
Introduction of the world’s first dipeptide solution for parenteral nutrition. Inauguration of the state-of-the-art infusions solutions plant (Friedberg, Hesse), the most modern one in Europe.
1999
Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe's leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home.
Launch of a new generation of hydroxyethyl starch for volume therapy.
2000
Fresenius Kabi accelerated its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America as well as expanding the service program.
2003
The business segment Fresenius HemoCare was reallocated within the Fresenius Group. Due to their similar technology platform, the Infusion Technology and Transfusion Technology Divisions were combined under one management and assigned to Fresenius Kabi.
2004
Fresenius Kabi strengthens its market positions with acquisitions in South Africa and Czech Republic as well as with a joint venture in Australia.
2005
Expansion of I.V. drug portfolio via acquisition of the Portugese pharmaceutical company Labesfal. |
| |
| |
|
| | | |
